Back to top
more

Avantor (AVTR)

(Delayed Data from NYSE)

$11.64 USD

11.64
18,282,825

+0.34 (3.01%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $11.64 0.00 (0.00%) 7:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AVTR Stock Declines as Q2 Earnings Miss Estimates, Revenues Down Y/Y

by Zacks Equity Research

Avantor stock dips more than 15% as Q2 EPS missed estimates, revenue declines year over year and lowers full-year guidance.

Zacks Equity Research

Avantor (AVTR) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates

by Zacks Equity Research

Avantor (AVTR) delivered earnings and revenue surprises of -4.00% and +0.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Teladoc (TDOC) Down 0.1% Since Last Earnings Report?

by Zacks Equity Research

Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y

by Zacks Equity Research

AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.

Zacks Equity Research

Compared to Estimates, Avantor (AVTR) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Avantor (AVTR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates

by Zacks Equity Research

Avantor (AVTR) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Danaher (DHR) delivered earnings and revenue surprises of 16.05% and 3.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold AVTR Stock in Your Portfolio for Now

by Zacks Equity Research

Avantor is set for growth with a strong portfolio and solid fourth quarter results, but challenges like customer losses and forex volatility pose potential risks.

Zacks Equity Research

Avantor Stock Declines Despite Q4 Earnings Beat, Margins Expand

by Zacks Equity Research

Despite AVTR's stability in proprietary chemicals and specialty procurement sales, it reports an overall soft fourth-quarter performance.

Zacks Equity Research

Avantor (AVTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Avantor, Inc. (AVTR) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Avantor (AVTR) delivered earnings and revenue surprises of 8% and 1.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Avantor, Inc. (AVTR) Q4 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 1.05% and 0.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

MD vs. AVTR: Which Stock Is the Better Value Option?

by Zacks Equity Research

MD vs. AVTR: Which Stock Is the Better Value Option?

Zacks Equity Research

MD vs. AVTR: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MD vs. AVTR: Which Stock Is the Better Value Option?

Zacks Equity Research

MD or AVTR: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. AVTR: Which Stock Is the Better Value Option?

Zacks Equity Research

MD or AVTR: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. AVTR: Which Stock Is the Better Value Option?

Zacks Equity Research

MD vs. AVTR: Which Stock Is the Better Value Option?

by Zacks Equity Research

MD vs. AVTR: Which Stock Is the Better Value Option?

Zacks Equity Research

Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down

by Zacks Equity Research

Despite AVTR's continued stability in the Education and Advanced Technology end markets, it reports an overall soft third-quarter performance.

Zacks Equity Research

Avantor (AVTR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Avantor (AVTR) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Avantor, Inc. (AVTR) Beats Q3 Earnings Estimates

by Zacks Equity Research

Avantor (AVTR) delivered earnings and revenue surprises of 4% and 0.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?